Celltrion: "Begzelma Listed in Formularies of Two Major U.S. PBMs"
Securing Coverage for 35% of the U.S. Insurance Market
High-Margin Follow-Up Products to Launch in the U.S. in the Second Half
"Performance Momentum of Existing Product Lineup to Continue"
Begzelma (active ingredient: bevacizumab), a treatment for metastatic colorectal and breast cancer sold by Celltrion, has been listed in the formularies of two major pharmacy benefit managers (PBMs) in the United States, paving the way for reimbursement.
According to Celltrion on July 7, Begzelma was recently included as a preferred drug, eligible for priority prescription, in both the public and private insurance formularies of Express Scripts (ESI), one of the three largest PBMs in the U.S., as well as in the public insurance formulary of another major PBM, Optum. Reimbursement coverage began for ESI public insurance and Optum on July 1, and coverage for ESI private insurance will commence in January next year.
The three largest PBMs in the U.S. pharmaceutical market collectively control about 80% of the total insurance market, giving them enormous influence. If a drug is not listed in the formularies managed by the PBMs, patients must pay the full product price without reimbursement, making it virtually impossible to access high-cost therapies. With this PBM listing, Begzelma has secured reimbursement coverage for more than 35% of the U.S. insurance market, providing a stable foundation for prescriptions.
According to pharmaceutical market research firm IQVIA, as of May, Begzelma achieved a market share of approximately 10.6% in the U.S., surpassing double digits for the first time since its launch and continuing its growth trend. Celltrion plans to further accelerate Begzelma's momentum by continuing negotiations for listings with other major PBMs.
With the performance of existing products, including Begzelma, Stekyma (active ingredient: ustekinumab), and Yuflyma (active ingredient: adalimumab), as well as the launch of high-margin follow-up products, Celltrion's U.S. business is expected to maintain its growth trajectory. In the second half of the year, the launch of the subcutaneous (SC) formulation of Aptozma (active ingredient: tocilizumab) and Omriclo (active ingredient: omalizumab) is set to further strengthen Celltrion’s portfolio in the U.S. market.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Celltrion representative stated, "With Begzelma now designated as a preferred drug in the formularies of major PBMs with significant influence in the U.S., we expect prescription volumes to rise sharply as a result of securing a reimbursement foundation. We will do our utmost to boost sales performance for Celltrion’s product lineup, thereby expanding our presence in the U.S. market."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.